Attention Shareholders: Don’t Miss the Eiger Biopharmaceuticals Class Action Deadline – Johnson Fistel Urges You to Submit Your EIGR Losses!

Eiger BioPharmaceuticals Class Action Lawsuit Update Shareholder rights law firm Johnson Fistel, LLP has announced that a class action lawsuit has commenced on behalf of investors of Eiger BioPharmaceuticals, Inc. (NASDAQ: EIGR). The class action is on behalf of shareholders who purchased Eiger securities between March 10, 2021 and October… SAN DIEGO, Dec. 05, 2022…

Read More

Wireless Telecom Group Sells CommAgility: A Major Move in the Radio Baseband and Software Industry

Wireless Telecom Group Announces the Sale of CommAgility, its Radio, Baseband and Software Segment, to E-Space Parsippany, New Jersey, USA, Dec. 05, 2022 (GLOBE NEWSWIRE) – Wireless Telecom Group, Inc. (NYSE American: WTT) (the “Company”) today announced it entered into a definitive agreement to sell its radio, baseband and software segment, CommAgility LTD., to global…

Read More

Breaking News: Eurozone Sentix Investor Confidence Soars to 21, Indicating an End to Recessions Before They Begin!

Eurozone Sentix Investor Confidence rose to -21, recession ends before it’s begun December numbers show positive trend Eurozone Sentix Investor Confidence saw a significant rise in December, with the index climbing from -30.9 to -21.0. This is the highest level recorded since June, indicating a promising outlook for the region’s economy. The Current Situation Index…

Read More

Unlocking the Potential: Aerosol Valves Market Projected to Reach US$3.1 Billion by 2032, Fueled by Automotive Industry Growth – Insights from Future Market Insights

The Growth of Aerosol Valves Market Rapid growth of cosmetics industry, innovation in aerosol valves, and continuous new product launches are some of the key trends shaping the market for aerosol valves. India Aerosol Valves Market is projected to expand at a CAGR of 6.0% during 2022-32 The aerosol valves market is witnessing a significant…

Read More

MaxCyte Partners with Curamys to Advance Cell and Gene Therapies for Rare Diseases: A Strategic Platform License Agreement

MaxCyte Signs Strategic Platform License with Curamys to Enable Advancements in Cell Fusion Technology ROCKVILLE, Md. and SEOUL, South Korea, Dec. 04, 2022 (GLOBE NEWSWIRE) — MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics… MaxCyte, Inc., a…

Read More

Unlocking the Secrets of the Bond Market: A Must-Watch for Traders This Week

Effects of Dollar Vulnerabilities on Bond Yields What the Technical Analysis is Telling Us Yields in the bond market are currently hovering just above their 100-day moving average, indicating a delicate balance between supply and demand. This suggests that investors are closely monitoring the performance of the dollar in relation to other currencies, particularly the…

Read More